Form 8-K - Current report
02 November 2023 - 7:59AM
Edgar (US Regulatory)
false
0001671502
0001671502
2023-10-26
2023-10-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 26, 2023
QUOIN
PHARMACEUTICALS LTD. |
(Translation of registrant’s name into English) |
State of Israel |
|
001-37846 |
|
92-2593104 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
42127 Pleasant Forest Court
Ashburn, VA |
|
20148-7349 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (703) 980-4182
Not applicable |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
American Depositary Shares, each representing five thousand (60,000) Ordinary Shares, no par value per share |
|
QNRX |
|
The Nasdaq Stock Market LLC |
Ordinary Shares, no par value per share* |
|
|
|
N/A |
| * | Not for trading, but only in connection with the registration of the American Depositary Shares pursuant
to requirements of the Securities and Exchange Commission. |
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers. |
At the Annual General Meeting of Shareholders
(“Annual Meeting”) of Quoin Pharmaceuticals Ltd. (“Quoin” or the “Company”), held on October 26, 2023,
shareholders approved: (i) amendments to the employment agreements of the Company’s Chief Executive Officer, Dr. Michael Myers,
and Chief Operating Officer, Denise Carter, providing for an increase to their respective annual base salaries by 9.5%, retroactive to
January 1, 2023, to $602,250 for Dr. Myers and $481,800 for Ms. Carter, (ii) 2022 bonuses for Dr. Myers and Ms. Carter of $247,500 and
$198,000, respectively, consistent with the terms of their employment agreements; and (iii) a grant of options to Dr. Myers and Ms. Carter,
under Quoin’s Amended and Restated Equity Incentive Plan (the “Plan”), to purchase 80,965 ADSs and 80,966 ADSs, respectively,
each at an exercise price per ADS of $5.75, vesting over a four-year period, with 20% of the ADS to be vested one year from October 26,
2023, and the balance vesting on an annual basis thereafter (20% the second and third year from October 26, 2023 and 40% the fourth year
from October 26, 2023).
Effective October 26, 2023, (i) the employment
agreement of the Company’s Chief Financial Officer, Gordon Dunn, was amended to provide for an increase to his annual base salary
by 9.5%, retroactive to January 1, 2023, to $394,200, and (ii) Mr. Dunn was awarded a 2022 bonus of $162,000, consistent with the terms
of his employment agreement, and granted an option to purchase 51,149ADSs, under the Plan, with the same exercise price per ADS and vesting
schedule as options granted to Dr. Myers and Ms. Carter.
ITEM 5.07 |
Submission of Matters to a Vote of Security Holders. |
The following is a summary of the matters voted on at the Annual Meeting,
with the votes set forth in ordinary shares of the Company:
|
(1) |
The shareholders elected the following directors to serve on the Board of Directors, to serve until Quoin’s 2024 annual meeting of shareholders and until such director’s successor is duly elected and qualified, or until such director’s earlier resignation or retirement, as follows: |
Directors | |
For | |
Against | |
Abstain | |
Brokers non-vote |
Dr. Michael Myers | |
4,714,440,000 | |
1,171,620,000 | |
770,400,000 | |
-- |
Denise Carter | |
5,738,640,000 | |
707,160,000 | |
210,660,000 | |
-- |
Joseph Cooper | |
5,743,800,000 | |
692,580,000 | |
220,080,000 | |
-- |
James Culverwell | |
5,720,880,000 | |
715,140,000 | |
220,440,000 | |
-- |
Dr. Dennis H. Langer | |
5,345,160,000 | |
1,115,640,000 | |
195,660,000 | |
-- |
Natalie Leong | |
5,754,360,000 | |
694,500,000 | |
207,600,000 | |
-- |
Michael Sember | |
5,734,440,000 | |
584,820,000 | |
337,200,000 | |
-- |
|
(2) |
The shareholders approved an amendment to Quoin’s Articles of Association, as amended (the “Articles of Association”), to increase the Company’s registered share capital from 500,000,000,000 ordinary shares, no par value, to 6,000,000,000,000 ordinary shares, no par value, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
4,338,900,000 |
|
2,218,020,000 |
|
99,540,000 |
|
-- |
|
(3) |
The shareholders approved an amendment to Quoin’s Articles of Association to effect a reverse split of the Company’s ordinary shares at a ratio of 1-for-60,000, effective on a date to be determined by the Board of Directors of the Company, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
4,318,680,000 |
|
2,230,140,000 |
|
107,640,000 |
|
-- |
|
(4) |
The shareholders approved an amendment to the terms of employment of Quoin’s Chief Executive Officer, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
2,535,360,000 |
|
1,501,620,000 |
|
55,020,000 |
|
-- |
|
(5) |
The shareholders approved an amendment to the terms of employment of Quoin’s Chief Operating Officer, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
4,655,340,000 |
|
1,847,220,000 |
|
153,900,000 |
|
-- |
|
(6) |
The shareholders approved an annual discretionary bonus under the terms of employment of Quoin’s Chief Executive Officer, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
1,929,840,000 |
|
1,678,440,000 |
|
29,100,000 |
|
-- |
|
(7) |
The shareholders approved an annual discretionary bonus under the terms of employment of Quoin’s Chief Operating Officer, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
1,943,280,000 |
|
1,631,220,000 |
|
544,920,000 |
|
-- |
|
(8) |
The shareholders approved a grant of options to Quoin’s Chief Executive Officer, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
2,128,020,000 |
|
1,908,960,000 |
|
54,540,000 |
|
-- |
|
(9) |
The shareholders approved a grant of options to Quoin’s Chief Operating Officer, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
2,222,100,000 |
|
1,746,540,000 |
|
56,700,000 |
|
-- |
|
(10) |
The shareholders approved, on a non-binding advisory basis, the compensation of Quoin’s named executive officers, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
4,510,560,000 |
|
1,855,140,000 |
|
290,760,000 |
|
-- |
|
(11) |
The shareholders approved, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of Quoin’s executive officers, as follows: |
1Y |
|
2 YR |
|
3 YR |
|
Abstain |
|
Brokers
non-vote |
1,677,840,000 |
|
65,340,000 |
|
4,545,480,000 |
|
285,840,000 |
|
-- |
|
(12) |
The shareholders approved changes to the compensation program for Quoin’s non-employee directors, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
4,434,720,000 |
|
2,085,300,000 |
|
136,440,000 |
|
-- |
|
(13) |
The shareholders approved the grant of options to Quoin’s non-employee directors, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
4,227,000,000 |
|
1,744,980,000 |
|
684,480,000 |
|
-- |
|
(14) |
The shareholders approved the appointment of Marcum LLP as Quoin’s independent registered public accounting firm until Quoin’s 2024 annual meeting of shareholders, as follows: |
For |
|
Against |
|
Abstain |
|
Brokers
non-vote |
6,058,620,000 |
|
404,820,000 |
|
193,020,000 |
|
-- |
Item 8.01. Other Events
Under Quoin’s non-employee directors’
compensation program approved by shareholders at the Annual General Meeting held on April 12, 2022, each non-employee director was
entitled to receive an annual base retainer of $60,000, as well as an annual option award under the Plan valued at $60,000. At the Annual
Meeting, the shareholders approved an increase of each non-employee director’s annual base retainer to $75,000 and a reduction of
the value of the option grant to a non-employee director under the Plan to approximately $44,000. Shareholders also approved at the Annual
Meeting, for each currently serving non-employee director, an annual grant of an option to purchase 7,652 ADSs, under the Plan, at an
exercise price per ADS of $5.75, vesting over a four-year period, with 20% of the ADSs to be vested one year from October 26, 2023, and
the balance vesting on an annual basis thereafter (20% the second and third year from October 26, 2023 and 40% the fourth year from October
26, 2023).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
Date: November 1, 2023 |
QUOIN PHARMACEUTICALS LTD. |
|
|
|
|
|
By: |
/s/ Gordon Dunn |
|
Name: |
Gordon Dunn |
|
Title: |
Chief Financial Officer |
v3.23.3
Cover
|
Oct. 26, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Oct. 26, 2023
|
Entity File Number |
001-37846
|
Entity Registrant Name |
QUOIN
PHARMACEUTICALS LTD.
|
Entity Central Index Key |
0001671502
|
Entity Tax Identification Number |
92-2593104
|
Entity Incorporation, State or Country Code |
L3
|
Entity Address, Address Line One |
42127 Pleasant Forest Court
|
Entity Address, City or Town |
Ashburn
|
Entity Address, State or Province |
VA
|
Entity Address, Postal Zip Code |
20148-7349
|
City Area Code |
703
|
Local Phone Number |
980-4182
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
American Depositary Shares, each representing five thousand (60,000) Ordinary Shares, no par value per share
|
Trading Symbol |
QNRX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From Apr 2024 to May 2024
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From May 2023 to May 2024